第 1 章 序論
1.8 第 1 章の参考文献
1. 2016 年版 カテーテル＆チューブ，IVR製品市場の中期予測と関連製品の徹底分析，株 式会社矢野経済研究所，2017年2月15日.
2. Nordon, I. M.; Hinchliffe, R. J.; Loftus, I. M.; Thompson, M. M., Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol 2011, 8 (2), 92-102.
3. Matsumoto, T.; Endo, J.; Hashida, K.; Ichikawa, H.; Kojima, S.; Takashimizu, S.; Watanabe, N.;
Yamagami, T.; Hasebe, T., Balloon-occluded transarterial chemoembolization using a 1.8-French tip Coaxial microballoon catheter for hepatocellular carcinoma: Technical and safety considerations. Minimally Invasive Therapy & Allied Technologies 2015, 24 (2), 94-100.
4. Matsumoto, T.; Kudo, T.; Endo, J.; Hashida, K.; Tachibana, N.; Murakoshi, T.; Hasebe, T., Transnodal lymphangiography and post-CT for protein-losing enteropathy in Noonan syndrome.
Minimally Invasive Therapy & Allied Technologies 2015, 24 (4), 246-249.
5. Matsumoto, T.; Endo, J.; Hashida, K.; Mizukami, H.; Nagata, J.; Ichikawa, H.; Kojima, S.;
Takashimizu, S.; Yamagami, T.; Watanabe, N.; Hasebe, T., Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization. Minimally Invasive Therapy &
Allied Technologies 2016, 25 (1), 22-28.
6. Matsumoto, T.; Ichikawa, H.; Imai, J.; Hayashi, T.; Tomita, K.; Mine, T.; Kojima, S.; Watanabe, N.; Hasebe, T., Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma. Anticancer Research 2017, 37 (6), 3183-3187.
7. Mine, T.; Matsumoto, T.; Endo, J.; Hashida, K.; Kojima, S.; Watanabe, N.; Hasebe, T., Balloon-occluded retrograde transvenous obliteration using a new microballoon for gastric varices.
Minimally Invasive Therapy & Allied Technologies 2017, 26 (3), 177-181.
8. Matsumoto, T.; Hasebe, T.; Baba, Y.; Chosa, K.; Kondo, S.; Yamada, S.; Yoshimatsu, R.; Kubota, T.; Fujitaka, K.; Awai, K.; Yamagami, T., Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer. Anticancer Research 2018, 38 (6), 3587-3592.
26
9. Matsumoto, T.; Tomita, K.; Suda, S.; Hashida, K.; Maegawa, S.; Hayashi, T.; Yamagami, T.;
Suzuki, T.; Hasebe, T., Microballoon-related interventions in various endovascular treatments of body trunk lesions. Minimally Invasive Therapy & Allied Technologies 2018, 27 (1), 2-10.
10. Mine, T.; Matsumoto, T.; Hayashi, T.; Tomita, K.; Masuda, K.; Kawashima, M.; Sakamaki, F.;
Hasebe, T., A Stepwise Embolization Strategy for a Bronchial Arterial Aneurysm: Proximal Coil and Distal Glue with the Optional Use of a Microballoon Occlusion System. Cardiovascular and Interventional Radiology 2018, 41 (8), 1267-1273.
11. ISO 10993-1:2018 Biological evaluation of medical devices -- Part 1: Evaluation and testing within a risk management process.
12. ISO 10993-2:2006 Biological evaluation of medical devices -- Part 2: Animal welfare requirements.
13. ISO 10993-3:2014 Biological evaluation of medical devices -- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity.
14. ISO 10993-4:2017 Biological evaluation of medical devices -- Part 4: Selection of tests for interactions with blood.
15. ISO 10993-5:2009 Biological evaluation of medical devices -- Part 5: Tests for in vitro cytotoxicity.
16. ISO 10993-6:2016 Biological evaluation of medical devices -- Part 6: Tests for local effects after implantation.
17. ISO 10993-7:2008 Biological evaluation of medical devices -- Part 7: Ethylene oxide sterilization residuals.
18. ISO 10993-9:2009 Biological evaluation of medical devices -- Part 9: Framework for identification and quantification of potential degradation products.
19. ISO 10993-10:2010 Biological evaluation of medical devices -- Part 10: Tests for irritation and skin sensitization.
20. ISO 10993-11:2017 Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity.
21. ISO 10993-12:2012 Biological evaluation of medical devices -- Part 12: Sample preparation and reference materials.
27
22. ISO 10993-13:2010 Biological evaluation of medical devices -- Part 13: Identification and quantification of degradation products from polymeric medical devices.
23. ISO 10993-14:2001 Biological evaluation of medical devices -- Part 14: Identification and quantification of degradation products from ceramics.
24. ISO 10993-15:2000 Biological evaluation of medical devices -- Part 15: Identification and quantification of degradation products from metals and alloys.
25. ISO 10993-16:2017 Biological evaluation of medical devices -- Part 16: Toxicokinetic study design for degradation products and leachables.
26. ISO 10993-17:2002 Biological evaluation of medical devices -- Part 17: Establishment of allowable limits for leachable substances.
27. ISO 10993-18:2005 Biological evaluation of medical devices -- Part 18: Chemical characterization of materials.
28. ISO/TS 10993-19:2006 Biological evaluation of medical devices -- Part 19: Physico-chemical, morphological and topographical characterization of materials.
29. ISO/TS 10993-20:2006 Biological evaluation of medical devices -- Part 20: Principles and methods for immunotoxicology testing of medical devices.
30. ISO/TR 10993-22:2017 Biological evaluation of medical devices -- Part 22: Guidance on nanomaterials.
31. Tanaka, M.; Motomura, T.; Ishii, N.; Shimura, K.; Onishi, M.; Mochizuki, A.; Hatakeyama, T., Cold crystallization of water in hydrated poly(2-methoxyethyl acrylate) (PMEA). Polymer International 2000, 49 (12), 1709-1713.
32. Tanaka, M.; Mochizuki, A.; Ishii, N.; Motomura, T.; Hatakeyama, T., Study of blood compatibility with poly(2-methoxyethyl acrylate). Relationship between water structure and platelet compatibility in poly(2-methoxyethylacrylate-co-2-hydroxyethylmethacrylate).
Biomacromolecules 2002, 3 (1), 36-41.
33. Tanaka, M.; Mochizuki, A., Effect of water structure on blood compatibility - thermal analysis of water in poly(meth)acrylate. Journal of Biomedical Materials Research Part A 2004, 68A (4),
684-28 695.
34. Tanaka, M.; Mochizuki, A., Clarification of the Blood Compatibility Mechanism by Controlling the Water Structure at the Blood-Poly(meth)acrylate Interface. Journal of Biomaterials Science-Polymer Edition 2010, 21 (14), 1849-1863.
35. Kim, S. W.; Wisniewski, S.; Lee, E. S.; Winn, M. L., Role of protein and fatty acid adsorption on platelet adhesion and aggregation at the blood-polymer interface. Journal of Biomedical Materials Research 1977, 11 (1), 23-31.
36. Nilsson, B.; Ekdahl, K. N.; Mollnes, T. E.; Lambris, J. D., The role of complement in biomaterial-induced inflammation. Molecular Immunology 2007, 44 (1-3), 82-94.
37. Brodbeck, W. G.; Colton, E.; Anderson, J. M., Effects of adsorbed heat labile serum proteins and fibrinogen on adhesion and apoptosis of monocytes/macrophages on biomaterials. Journal of Materials Science-Materials in Medicine 2003, 14 (8), 671-675.
38. De La Cruz, C.; Haimovich, B.; Greco, R. S., Immobilized IgG and fibrinogen differentially affect the cytoskeletal organization and bactericidal function of adherent neutrophils. Journal of Surgical Research 1998, 80 (1), 28-34.
39. Vroman, L., The life of an artificial device in contact with blood – initial events and their effect on its final-state. Bulletin of the New York Academy of Medicine 1988, 64 (4), 352-357.
40. Tsai, W. B.; Grunkemeier, J. M.; McFarland, C. D.; Horbett, T. A., Platelet adhesion to polystyrene-based surfaces preadsorbed with plasmas selectively depleted in fibrinogen, fibronectin, vitronectin, or von Willebrand's factor. Journal of Biomedical Materials Research 2002, 60 (3), 348-359.
41. Drachman, D. E.; Edelman, E. R.; Seifert, P.; Groothuis, A. R.; Bornstein, D. A.; Kamath, K. R.;
Palasis, M.; Yang, D.; Nott, S. H.; Rogers, C., Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. Journal of the American College of Cardiology 2000, 36 (7), 2325-2332.
42. Zarins, C. K.; White, R. A.; Schwarten, D.; Kinney, E.; Diethrich, E. B.; Hodgson, K. J.; Fogarty, T. J.; Investigators Medtronic AneuRx Multicenter, C., AneuRx stent graft versus open surgical
29
repair of abdominal aortic aneurysms: Multicenter prospective clinical trial. Journal of Vascular Surgery 1999, 29 (2), 292-306.
43. Diethrich, E. B.; Ndiaye, M.; Raid, D. B., Stenting in the carotid artery: Initial experience in 110 patients. Journal of Endovascular Surgery 1996, 3 (1), 42-62.
44. Schillinger, M.; Sabeti, S.; Loewe, C.; Dick, P.; Amighi, J.; Mlekusch, W.; Schlager, O.; Cejna, M.; Lammer, J.; Minar, E., Calloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. New England Journal of Medicine 2006, 354 (18), 1879-1888.
45. Huang, N.; Yang, P.; Leng, Y. X.; Chen, J. Y.; Sun, H.; Wang, J.; Wang, G. J.; Ding, P. D.; Xi, T.
F.; Leng, Y., Hemocompatibility of titanium oxide films. Biomaterials 2003, 24 (13), 2177-2187.
46. LeBreton, H.; Plow, E. F.; Topol, E. J., Role of platelets in restenosis after percutaneous coronary revascularization. Journal of the American College of Cardiology 1996, 28 (7), 1643-1651.
47. McGuigan, A. P.; Sefton, M. V., The influence of biomaterials on endothelial cell thrombogenicity.
Biomaterials 2007, 28 (16), 2547-2571.
48. Schwartz, S. M.; Deblois, D.; Obrien, E. R. M., THE INTIMA - SOIL FOR ATHEROSCLEROSIS AND RESTENOSIS. Circulation Research 1995, 77 (3), 445-465.
49. Stone, G. W.; Ellis, S. G.; Cox, D. A.; Hermiller, J.; O'Shaughnessy, C.; Mann, J. T.; Turco, M.;
Caputo, R.; Bergin, P.; Greenberg, J.; Popma, J. J.; Russell, M. E., A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. New England Journal of Medicine 2004, 350 (3), 221-231.
50. Brossollet, L. J., MECHANICAL ISSUES IN VASCULAR GRAFTING - A REVIEW.
International Journal of Artificial Organs 1992, 15 (10), 579-584.
51. Meinhart, J.; Deutsch, M.; Zilla, P., Eight years of clinical endothelial cell transplantation - Closing the gap between prosthetic grafts and vein grafts. Asaio Journal 1997, 43 (5), M515-M521.
52. Meinhart, J. G.; Deutsch, M.; Fischlein, T.; Howanietz, N.; Froschl, A.; Zilla, P., Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts. Annals of Thoracic Surgery 2001, 71 (5), S327-S331.
53. Somberg, J.; Weinberger, J., Late stent thrombosis: Problem or not? American Journal of
30 Cardiology 2007, 99 (7), 1020-1023.
54. Parodi, J. C.; Palmaz, J. C.; Barone, H. D., Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Annals of vascular surgery 1991, 5 (6), 491-499.
55. Baguneid, M. S.; Seifalian, A. M.; Salacinski, H. J.; Murray, D.; Hamilton, G.; Walker, M. G., Tissue engineering of blood vessels. British Journal of Surgery 2006, 93 (3), 282-290.
56. Brown, D. B.; Nikolic, B.; Covey, A. M.; Nutting, C. W.; Saad, W. E. A.; Salem, R.; Sofocleous, C. T.; Sze, D. Y., Quality Improvement Guidelines for Transhepatic Arterial Chemoembolization, Embolization, and Chemotherapeutic Infusion for Hepatic Malignancy. Journal of Vascular and Interventional Radiology 2012, 23 (3), 287-294.
57. Sakamoto, I.; Aso, N.; Nagaoki, K.; Matsuoka, Y.; Uetani, M.; Ashizawa, K.; Iwanaga, S.; Mori, M.; Morikawa, M.; Fukuda, T.; Hayashi, K.; Matsunaga, N., Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998, 18 (3), 605-619.
58. Takayasu, K.; Moriyama, N.; Muramatsu, Y.; Shima, Y.; Ushio, K.; Yamada, T.; Kishi, K.;
Hasegawa, H., Gallbladder infarction after hepatic artery embolization. American Journal of Roentgenology 1985, 144 (1), 135-138.
31